Recent Clinical Trials on Natural Products and Traditional Chinese Medicine Combating the COVID-19

被引：0
作者：
Shivraj Hariram Nile
Guoyin Kai
机构：
[1] Zhejiang Chinese Medical University,Laboratory of Medicinal Plant Biotechnology, College of Pharmacy
来源：
Indian Journal of Microbiology | 2021年 / 61卷
关键词：
COVID-19; Natural products; TCM; SARS-CoV-2; Clinical trials;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing potentially fatal coronavirus disease-19 (COVID-19), with a significant health and economic burden around the globe. Currently many clinical studies are undergoing but still there is no any specific approved therapy or drug established for effective treatment of COVID-19. This review aimed to analyses various clinical studies which have been registered in www.clinicaltrials.gov and http://www.chictr.org.cn were registered with natural plant-based medicines and Traditional Chinese medicine (TCM) for discovering effective treatment and prevention of COVID-19. Total 46 and 64 natural drug and TCM interventions were identified which mainly determined the preventive strategies and possible treatments for COVID-19 infection. We identified that most of the clinical trial undergoing on natural compound like heparin and vitamin C as therapeutic agents and immune boosters for against COVID-19. Traditional Chinese medicines and herbal medicines can be effectively used as a preventive therapy against COVID-19 and after successful clinical trials and these potential therapies can be promoted by countries around the world.
引用
收藏
页码：10 / 15
页数：5
相关论文
共 144 条
[1]  
Zhao W(2020)A systematic approach is needed to contain COVID-19 globally Sci Bull 65 876-878
[2]  
Zhang J(2020)Deploying biomolecules as antii-COVID-19 agents Indian J Microbiol 60 263-268
[3]  
Meadows ME(2020)Diet, gut microbiota and COVID-19 Indian J Microbiol 60 420-429
[4]  
Liu Y(2011)Genomic analysis reveals versatile organisms for quorum quenching enzymes: acyl-homoserine lactone-acylase and-lactonase Open Microbiol J 5 1-11
[5]  
Hua T(2014)Evolution of resistance to quorum-sensing inhibitors Microb Ecol 68 13-23
[6]  
Fu B(2013)Extending the limits of Biotechnol Adv 31 1543-1561
[7]  
Patel SKS(2020) for novel biotechnological applications Trends Pharmacol Sci 41 363-382
[8]  
Lee JK(2020)Ongoing clinical trials for the management of the COVID-19 pandemic Mayo Clin Proc 95 1578-1580
[9]  
Kalia VC(2020)Clinical trial endpoints in severe COVID-19 Sci Mag 53 66-70
[10]  
Rishi P(2020)WHO launches global megatrial of the four most promising coronavirus treatments? Cytokine Growth Factor Rev 86 170-174
12345678910